R Izu-Belloso, I Gainza-Apraiz, P Ortiz-Romero, O Servitje-Bedate, R Fernández de Misa-Cabrera, Y Peñate-Santana, B Hernandez-Machin, T Estrach-Panella, M Llamas-Velasco, J I Yanguas-Bayona, M Morillo-Andujar, E Acebo-Mariñas, S Perez-Gala, J C Armario-Hita, P Sanchez-Sambucety, A Ortiz-Brugues, C Eguren-Michelena, I Bielsa-Marsol, A Lopez-Pestaña, M Blanes-Martinez, M Fernandez-Guarino, I Lopez-Lerma
BACKGROUND AND OBJECTIVES: Bexarotene has been approved to treat advanced stage cutaneous T-cell lymphomas (CTCL) since 1999. However, very few data have been published on its long-term safety and efficacy profile. The aim of this study is to determine the tolerability to bexarotene and outcomes by collecting the 2nd largest case series to date on its long-term use vs CTCL. MATERIAL AND METHOD: This was a multicenter retrospective review of 216 patients with mycosis fungoides (174), or Sézary syndrome (42) on a 10-year course of bexarotene alone or in combinationwith other therapies at 19 tertiary referral teaching hospitals...
February 21, 2024: Actas Dermo-sifiliográficas